E3 PreliminaryPreliminaryPEM not requiredMachine draft
The Potential Role of Hypothalamic Phospholipid Liposomes in the Supportive Therapy of Some Manifestations of Post-COVID-19 Condition: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Brain Fog.
Menichetti, Francesco · Journal of clinical medicine · 2023 · DOI
Quick Summary
This article discusses how a treatment called hypothalamic phospholipid liposomes might help with ME/CFS and brain fog symptoms in people with Long COVID. These liposomes are small fatty particles that are already available as a supportive treatment for brain and hormone-related problems. The authors suggest this treatment could be helpful based on how it works and their early clinical experiences, though more rigorous testing is still needed.
Why It Matters
This work addresses a critical clinical need in ME/CFS and Long COVID management, where effective treatments remain limited. By proposing a mechanistically plausible therapeutic approach grounded in the neuroendocrine and metabolic dysfunction underlying these conditions, it opens a potential avenue for symptom management that could improve quality of life for patients with ME/CFS and related post-viral conditions.
Observed Findings
- - Cerebral metabolic alterations and neuroendocrine disorders are significant components of Post-COVID-19 condition pathophysiology
- - Hypothalamic phospholipid liposomes have been marketed for several years as adjuvant therapy for cerebral metabolic alterations from neuroendocrine disorders
- - Current therapeutic options for ME/CFS and brain fog in Long COVID are substantially lacking
- - Authors' preliminary clinical experience suggests potential effectiveness of this approach
Inferred Conclusions
- - Hypothalamic phospholipid liposomes represent a pharmacologically plausible option for managing PCC-associated symptoms
- - The mechanism of action of these liposomes aligns with proposed pathophysiological mechanisms in ME/CFS and Long COVID
- - Controlled clinical research is necessary to determine whether theoretical potential translates to clinical benefit
Remaining Questions
- - What are the results of controlled clinical trials testing hypothalamic phospholipid liposomes in ME/CFS or Long COVID populations?
- - What is the optimal dosing and duration of treatment with these liposomes for PCC symptoms?
- - How do hypothalamic phospholipid liposomes compare in efficacy to other emerging treatments for ME/CFS?
What This Study Does Not Prove
This editorial does not provide evidence from controlled clinical trials that hypothalamic phospholipid liposomes are effective for ME/CFS or Long COVID. The preliminary clinical experience mentioned is anecdotal rather than systematically collected, and the study does not establish causation or quantify treatment efficacy. This is theoretical speculation supported by mechanism, not proof of clinical benefit.
Tags
EXPLORATORYPEM NOT DEFINED
Metadata
- DOI
- 10.3390/jcm12175478
- PMID
- 37685544
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →